332 studies on GLP-1R mechanism curated from PubMed, ClinicalTrials.gov, and EuropePMC. Updated daily.
This research is highly significant as it targets a critical unmet need in Type 2 Diabetes management: patients who do not achieve adequate glycemic control even with potent GLP-1 or GLP-1/GIP receptor agonists. LY345…
This Phase 2a study is crucial because it targets a specific genetic subtype of MASLD that is often more aggressive and difficult to treat. ALN-PNP works by reducing the PNPLA3 protein, which is implicated in liver fa…
This commentary underscores the urgent need for a proactive public health strategy to manage the societal implications of GLP-1RA proliferation. The authors argue that without clear guidelines and public education, th…
The widespread use of GLP-1 RAs for managing diabetes and obesity makes understanding their perioperative implications critically important for patient safety. This study directly addresses the potential for increased…
As this study is currently "NOT_YET_RECRUITING" and is scheduled to begin in 2026, no results or specific data are available at this time. The primary objective is to determine if there are significant differences in …
This study is crucial because it seeks to uncover a novel mechanism by which semaglutide promotes weight loss, specifically through its impact on brown adipose tissue (BAT). Understanding this pathway could lead to mo…
This study holds significant promise for overweight and obese women struggling with infertility, potentially offering a novel therapeutic strategy to improve IVF success rates. If Semaglutide pre-treatment proves effe…
This diagnostic study, while listed as completed, has not yet published its specific findings regarding gastric contents in patients on semaglutide, with the official completion date set for 2025-05-31. However, the f…
This study is significant because it provides valuable real-world evidence on Semaglutide's effectiveness, complementing the data from highly controlled clinical trials. Understanding how a drug performs in diverse pa…
Semaglutide is currently not FDA-approved for Type 1 Diabetes, making this research critical for exploring new therapeutic avenues in a population with significant unmet medical needs. If the trial demonstrates positi…
The successful demonstration of semaglutide's safety and tolerability in CFRD patients would be a significant step forward, potentially offering a novel therapeutic avenue beyond insulin. If proven safe and effective …
Understanding how liver function affects oral semaglutide's pharmacokinetics is crucial for dose adjustments and patient safety, especially given the widespread use of GLP-1 receptor agonists for type 2 diabetes. The …
This study holds significant promise for addressing a critical unmet medical need: effective treatment for early-onset, treatment-resistant obesity in young adults. If successful, the RESETTLE Study could establish se…
The discontinuation of GLP-1 agonists often leads to weight regain and a return of metabolic challenges, including elevated triglycerides, which are risk factors for cardiovascular disease. If RDX-002 proves effective…
This research is critically important as it will provide evidence-based guidance for managing incretin-based therapies in patients undergoing upper endoscopy, potentially enhancing patient safety and procedural effici…
This case, if substantiated by detailed clinical data, suggests that Semaglutide could represent a novel and effective therapeutic option for patients with Ulcerative Colitis, particularly those who also suffer from o…
This case report highlights a potential novel therapeutic avenue for ulcerative colitis, suggesting that GLP-1 RAs like semaglutide might offer benefits beyond metabolic control. The observed symptomatic remission and…
The successful completion of this trial could lead to the availability of a new semaglutide injection, potentially increasing access and offering more treatment options for Type 2 Diabetes patients. If the investigati…
This large-scale, pragmatic trial is crucial because it directly compares two leading therapeutic strategies for Type 2 Diabetes patients at high risk for cardiovascular and kidney complications. The findings could pr…
This pilot study holds significant promise, as successful integration of weight management strategies could potentially improve treatment efficacy and long-term outcomes for endometrial cancer patients. If tirzepatide…
Finding effective strategies to prevent weight regain after discontinuing GLP-1 agonists is critically important for long-term obesity management and patient well-being. This trial could provide evidence for new stand…
If successful, this study could establish semaglutide as a safe and effective treatment option for glucose control in patients with Type 2 Diabetes and End Stage Renal Disease on dialysis. This is a particularly chall…
Understanding the safety and tolerability of BI 1820237 is a critical first step in its development as a potential new treatment for overweight and obesity. If BI 1820237 demonstrates a favorable safety profile and pr…
This study addresses a critical need for practical, accessible dietary recommendations to complement GLP-1 RA therapy, potentially enhancing patient outcomes beyond just weight loss. If successful, it could provide a …
This clinical trial is profoundly significant as it explores a novel and promising therapeutic approach for ADPKD, a disease with limited treatment options and a high burden on patients. If successful, this research c…
If tirzepatide proves safe and effective, it could represent a significant therapeutic advancement for individuals with Type 1 Diabetes who struggle with obesity or overweight. Currently, there are limited pharmacolog…
This real-world study is crucial for understanding the practical effectiveness of oral semaglutide in a specific demographic, providing valuable data beyond controlled clinical trials. The findings, once published, co…
Understanding the genetic underpinnings of oral semaglutide response is crucial for advancing personalized medicine in prediabetes and obesity. This research could pave the way for personalized treatment strategies, o…
This trial holds significant promise as it explores a novel therapeutic strategy for a complex and underserved patient population. If semaglutide proves effective in reducing alcohol intake and smoking, it could offer…
Obesity-related male infertility is a growing concern, and current treatments often lack sustained efficacy or adherence. This trial holds the potential to identify a novel and effective pharmacological intervention f…